However, while CETN1 could be an ideal target for the diagnosis and treatment of PDAC and prostate cancer in patients expressing this biomarker due to its specific expression and role in cell division ; the anti‐CETN1 antibodies available on the market do not sufficiently discriminate between CETN1 and CETN2, hampering their use as effective oncology biomarker detectors and therapeutics. This evidence concerns the gene CETN1 and Familial prostate cancer.